Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Lung Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 63 articles: HTML format

Single Articles

April 2025
1. HUGHES DJ, Chand G, Johnson J, Tegala R, et al
   PD-L1 imaging with [(99m)Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.
   Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02991.
   PubMed     Abstract available
   
   
   
2. COLANGELO T, Mazzarelli F, Cuttano R, Dama E, et al
   Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer.
   Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02982.
   PubMed     Abstract available
   
   
   
3. WANG M, Kim RY, Kohonen-Corish MRJ, Chen H, et al
   Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence.
   Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02999.
   PubMed     Abstract available
   
   
   
4. LIN X, Liu Z, Zhou K, Li Y, et al
   Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC.
   Br J Cancer. 2025;132:558-568.
   PubMed     Abstract available
   
   
   
5. ZHANG W, Wang J, Liang J, He Z, et al
   RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.
   Br J Cancer. 2025;132:569-579.
   PubMed     Abstract available
   
   
   
6. HONG CT, Yang YE, Juan HF, Chang CP, et al
   GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by attenuating STAT1 translocation to downregulate the type I IFN pathway.
   Br J Cancer. 2025;132:622-634.
   PubMed     Abstract available
   
   
   January 2025
7. WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al
   Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.
   Br J Cancer. 2025 Jan 7. doi: 10.1038/s41416-024-02926.
   PubMed    
   
   
   December 2024
8. CUTTY SJ, Hughes FA, Ortega-Prieto P, Desai S, et al
   Pro-survival roles for p21(Cip1/Waf1) in non-small cell lung cancer.
   Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02928.
   PubMed     Abstract available
   
   
   
9. LIU C, Reger M, Fan H, Wang J, et al
   Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
   Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
   PubMed     Abstract available
   
   
   
10. POPAT S, Januszewski A, O'Brien M, Ahmad T, et al
    Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
    Br J Cancer. 2024 Dec 5. doi: 10.1038/s41416-024-02901.
    PubMed     Abstract available
    
    
    November 2024
11. NORONHA V, Menon N, Patil VM, Shah M, et al
    Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02913.
    PubMed     Abstract available
    
    
    
12. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    PubMed     Abstract available
    
    
    
13. WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al
    Cardiotoxicity following thoracic radiotherapy for lung cancer.
    Br J Cancer. 2024 Nov 6. doi: 10.1038/s41416-024-02888.
    PubMed     Abstract available
    
    
    
14. HEKTOEN HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, et al
    Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
    Br J Cancer. 2024 Nov 3. doi: 10.1038/s41416-024-02895.
    PubMed     Abstract available
    
    
    
15. WEI J, Zhou S, Chen G, Chen T, et al
    GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression.
    Br J Cancer. 2024;131:1529-1542.
    PubMed     Abstract available
    
    
    
16. CHANDOURI B, Naves T, Yassine M, Ikhlef L, et al
    Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC.
    Br J Cancer. 2024;131:1425-1436.
    PubMed     Abstract available
    
    
    
17. LIU X, Min Q, Cheng X, Zhang W, et al
    Quiescent cancer cells induced by high-density cultivation reveals cholesterol-mediated survival and lung metastatic traits.
    Br J Cancer. 2024;131:1591-1604.
    PubMed     Abstract available
    
    
    October 2024
18. WANG Y, Ju X, Hua R, Chen J, et al
    Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.
    Br J Cancer. 2024 Oct 25. doi: 10.1038/s41416-024-02856.
    PubMed     Abstract available
    
    
    
19. MANDAL T, Shukla D, Khan MMA, Ganesan SK, et al
    The EXO1/Poleta/Poliota axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02840.
    PubMed     Abstract available
    
    
    August 2024
20. MIGLIETTA G, Russo M, Capranico G, Marinello J, et al
    Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02821.
    PubMed     Abstract available
    
    
    
21. ABDIPOURBOZORGBAGHI M, Vancura A, Radpour R, Haefliger S, et al
    Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC).
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02831.
    PubMed     Abstract available
    
    
    
22. ROGERS I, Cooper M, Memon A, Forbes L, et al
    The effect of comorbidities on diagnostic interval for lung cancer in England: a cohort study using electronic health record data.
    Br J Cancer. 2024 Aug 23. doi: 10.1038/s41416-024-02824.
    PubMed     Abstract available
    
    
    
23. NAGELBERG AL, Sihota TS, Chuang YC, Shi R, et al
    Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response.
    Br J Cancer. 2024;131:534-550.
    PubMed     Abstract available
    
    
    
24. BUDCZIES J, Romanovsky E, Kirchner M, Neumann O, et al
    KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
    Br J Cancer. 2024;131:524-533.
    PubMed     Abstract available
    
    
    July 2024
25. JEONG H, Koh J, Kim S, Song SG, et al
    Correction: Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Br J Cancer. 2024 Jul 30. doi: 10.1038/s41416-024-02798.
    PubMed    
    
    
    June 2024
26. ZHAO Y, Zheng Y, Fu J, Zhang J, et al
    KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer.
    Br J Cancer. 2024 Jun 29. doi: 10.1038/s41416-024-02772.
    PubMed     Abstract available
    
    
    
27. GULIKERS JL, Otten LS, Hendriks LEL, Winckers K, et al
    Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
    Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02744.
    PubMed     Abstract available
    
    
    
28. KATO T, Yang JC, Ahn MJ, Sakai H, et al
    Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Br J Cancer. 2024;130:1679-1686.
    PubMed     Abstract available
    
    
    May 2024
29. YOSHIMURA A, Horinaka M, Yaoi T, Ono H, et al
    Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
    Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727.
    PubMed     Abstract available
    
    
    
30. MALAPELLE U, Leighl N, Addeo A, Hershkovitz D, et al
    Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02709.
    PubMed     Abstract available
    
    
    
31. JEONG H, Koh J, Kim S, Song SG, et al
    Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Br J Cancer. 2024 May 10. doi: 10.1038/s41416-024-02698.
    PubMed     Abstract available
    
    
    April 2024
32. LI C, Liu L, You R, Li Y, et al
    Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
    Br J Cancer. 2024 Apr 9. doi: 10.1038/s41416-024-02678.
    PubMed     Abstract available
    
    
    
33. MATHIESON L, Koppensteiner L, Dorward DA, O'Connor RA, et al
    Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
    Br J Cancer. 2024 Apr 6. doi: 10.1038/s41416-024-02671.
    PubMed     Abstract available
    
    
    
34. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    PubMed     Abstract available
    
    
    
35. GORGULHO J, Roderburg C, Beier F, Bokemeyer C, et al
    Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
    Br J Cancer. 2024;130:1013-1022.
    PubMed     Abstract available
    
    
    
36. KANAHORI M, Shimada E, Matsumoto Y, Endo M, et al
    Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8(+) T cell infiltration.
    Br J Cancer. 2024;130:1083-1095.
    PubMed     Abstract available
    
    
    March 2024
37. HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al
    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662.
    PubMed     Abstract available
    
    
    
38. FU X, Liu S, Cao D, Li C, et al
    Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
    Br J Cancer. 2024;130:716-727.
    PubMed     Abstract available
    
    
    
39. BLANCO E, Silva-Pilipich N, Bocanegra A, Chocarro L, et al
    Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
    Br J Cancer. 2024;130:869-879.
    PubMed     Abstract available
    
    
    February 2024
40. BLECHTER B, Wong JYY, Chien LH, Shiraishi K, et al
    Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02592.
    PubMed     Abstract available
    
    
    
41. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Correction: Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02603.
    PubMed    
    
    
    
42. FONT A, Mellado B, Climent MA, Virizuela JA, et al
    Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
    Br J Cancer. 2024;130:434-441.
    PubMed     Abstract available
    
    
    January 2024
43. REN Z, Dharmaratne M, Liang H, Benard O, et al
    Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1alpha.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522.
    PubMed     Abstract available
    
    
    
44. MEZQUITA L, Oulhen M, Aberlenc A, Deloger M, et al
    Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
    Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02535.
    PubMed     Abstract available
    
    
    
45. LEONETTI A, Verze M, Minari R, Perrone F, et al
    Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
    Br J Cancer. 2024;130:135-142.
    PubMed     Abstract available
    
    
    December 2023
46. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2023 Dec 30. doi: 10.1038/s41416-023-02553.
    PubMed     Abstract available
    
    
    
47. CHEN B, Yao W, Li X, Lin G, et al
    A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02519.
    PubMed     Abstract available
    
    
    
48. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    PubMed     Abstract available
    
    
    
49. THOMPSON JC, Scholes DG, Carpenter EL, Aggarwal C, et al
    Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.
    Br J Cancer. 2023;129:1893-1902.
    PubMed     Abstract available
    
    
    November 2023
50. ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al
    Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
    Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491.
    PubMed     Abstract available
    
    
    
51. QU FJ, Zhou Y, Wu S
    Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases.
    Br J Cancer. 2023 Nov 9. doi: 10.1038/s41416-023-02482.
    PubMed     Abstract available
    
    
    
52. HUNTER B, Argyros C, Inglese M, Linton-Reid K, et al
    Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis.
    Br J Cancer. 2023 Nov 6. doi: 10.1038/s41416-023-02480.
    PubMed     Abstract available
    
    
    
53. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
    Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
    Br J Cancer. 2023 Nov 3. doi: 10.1038/s41416-023-02481.
    PubMed    
    
    
    
54. TANG M, Burgess JT, Fisher M, Boucher D, et al
    Targeting the COMMD4-H2B protein complex in lung cancer.
    Br J Cancer. 2023 Nov 1. doi: 10.1038/s41416-023-02476.
    PubMed     Abstract available
    
    
    
55. SHEN M, Liu S, Toland A, Hsu EC, et al
    ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
    Br J Cancer. 2023;129:1818-1828.
    PubMed     Abstract available
    
    
    October 2023
56. JANI BD, Sullivan MK, Hanlon P, Nicholl BI, et al
    Personalised lung cancer risk stratification and lung cancer screening: do general practice electronic medical records have a role?
    Br J Cancer. 2023 Oct 25. doi: 10.1038/s41416-023-02467.
    PubMed     Abstract available
    
    
    
57. YANG Z, Zhu J, Yang T, Tang W, et al
    Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma.
    Br J Cancer. 2023;129:1397-1408.
    PubMed     Abstract available
    
    
    
58. SICARD G, Protzenko D, Giacometti S, Barlesi F, et al
    Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
    Br J Cancer. 2023;129:1373-1382.
    PubMed     Abstract available
    
    
    
59. PARRA ER, Ilie M, Wistuba II, Hofman P, et al
    Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.
    Br J Cancer. 2023;129:1417-1431.
    PubMed     Abstract available
    
    
    September 2023
60. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
    Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
    Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02427.
    PubMed     Abstract available
    
    
    
61. GASSLER N, Zhang C, Wenger T, Schnabel PA, et al
    Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
    Br J Cancer. 2023 Sep 18. doi: 10.1038/s41416-023-02433.
    PubMed    
    
    
    
62. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
    Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
    Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
    PubMed     Abstract available
    
    
    
63. YANG Y, Xu S, Jia G, Yuan F, et al
    Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
    Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.